Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Department of Maternal and Child Health, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2215149. doi: 10.1080/21645515.2023.2215149.
Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs. Vaccines can contribute to combating antimicrobial resistance by reducing the incidence of resistant disease cases and lowering overall antibiotic use. Greater utilization and investments in vaccines as a tool for combating AMR might be hampered by limited economic evidence demonstrating the AMR-related value of vaccines. We reviewed the existing literature to assess the state of evidence. We found two modeling studies that provided estimates of AMR-related costs averted by pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness. We did not find any cost-effectiveness studies that directly examined the cost-effectiveness of vaccines in slowing the development of AMR. Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.
抗菌药物耐药性（AMR）是一种全球公共卫生威胁，可导致大量发病和死亡，并造成巨大的经济成本。疫苗可通过减少耐药性疾病病例的发生并降低总体抗生素使用量，为应对抗菌药物耐药性做出贡献。由于证明疫苗对抗 AMR 相关价值的经济证据有限，因此，更广泛地利用和投资疫苗作为对抗 AMR 的工具可能会受到阻碍。我们回顾了现有文献，以评估证据状况。我们发现了两项建模研究，这些研究提供了通过接种肺炎球菌疫苗避免的与 AMR 相关成本的估计，以及一些仅关注血清型替代对疫苗总体成本效益影响的成本效益研究。我们没有发现任何直接研究疫苗在减缓 AMR 发展方面的成本效益的成本效益研究。关于疫苗在控制 AMR 方面的成本效益和经济价值的进一步证据，可以帮助为资源分配决策提供信息，并指导发展重点。
